Previous Close | 5.61 |
Open | 5.61 |
Bid | 5.91 x 200 |
Ask | 7.28 x 200 |
Day's Range | 5.59 - 5.99 |
52 Week Range | 1.04 - 10.97 |
Volume | |
Avg. Volume | 165,096 |
Market Cap | 296.486M |
Beta (5Y Monthly) | 2.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights Generated first quarter 2024 total revenue of $19.3 mil
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectiv
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company’s management will discuss the results during a conference call beginnin